Blisibimod (A 623)蛋白抗体，Research Grade Blisibimod抗体，uniprot Q9Y275，红斑狼疮研究

发布人：武汉佰乐博生物技术有限公司

发布日期:2024/10/12 13:57:22

关键词：Blisibimod，A-623，系统性红斑狼疮，红斑狼疮研究，BAFF, ZTNF4, BLYS, Tumor necrosis factor ligand superfamily member 13B, Dendritic cell-derived TNF-like molecule, TALL-1, TNF- and APOL-related leukocyte expressed ligand 1, BLyS, B lymphocyte stimulator, TNFSF13B, CD257, TNFSF20, TALL1, B-cell-activating factor，Q9Y275

一、产品描述

Blisibimod (A 623) 是一种有效和选择性的四价B细胞激活因子(BAFF)抑制剂。Blisibimod可用于系统性红斑狼疮(SLE)的研究。

二、抗体详情

Research Grade Blisibimod

▼

▲

靶点

BAFF, ZTNF4, BLYS, Tumor necrosis factor ligand superfamily member 13B, Dendritic cell-derived TNF-like molecule, TALL-1, TNF- and APOL-related leukocyte expressed ligand 1, BLyS, B lymphocyte stimulator, TNFSF13B, CD257, TNFSF20, TALL1, B-cell-activating factor

货号

DHJ85305

形态

Liquid

纯度

>95% as determined by SDS-PAGE.

同型

Fusion - [peptide 16-mer - peptide 19-mer]2 - IGHG1 Fc (Fragment constant)

应用

Research Grade Biosimilar

别名

A-623

表达系统

Mammalian Cells

注意

仅供科研使用

三、已发表文献

▼

▲

Update on clinical trials in systemic lupus erythematosus. PMID: 27314466

Biotherapies in systemic lupus erythematosus: New targets. PMID: 27663753

Spotlight on blisibimod and its potential in the treatment of systemic lupus erythematosus: evidence to date. PMID: 28331294

A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the PEARL-SC study. PMID: 24748629

佰乐博生物作为法国AntibodySystem和ProteoGenix在亚洲的总代理商，提供近30,000种生命科学试剂，核心产品涵盖蛋白、抗体和试剂盒，旨在为科研工作者提供专业、全面、可靠的试剂支持，推动生命科学研究的深入发展。

试剂 | 耗材 | 定制 | 实验服务 | 供应链

免费热线：027-65279366 /18162686757

QQ：2663991332

咨询邮箱：info@biolabreagent.com